Ionis Pharmaceuticals (MEX:IONS) Total Liabilities: MXN53,351 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
65 GF Score
Price MXN1,150.00
GF Value MXN782.91
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Total Liabilities?

Ionis Pharmaceuticals MEX:IONS 65 Total Liabilities is MXN53,351 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 65/100 and a GF Value™ of MXN782.91. The stock has 8 warning signs investors should review.

Ionis Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was MXN53,351 Mil.

Ionis Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 (MXN44,303.52 Mil) to Dec. 2025 (MXN54,642.74 Mil) but then declined from Dec. 2025 (MXN54,642.74 Mil) to Mar. 2026 (MXN53,350.74 Mil).

Ionis Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (MXN44,190.52 Mil) to Dec. 2024 (MXN50,373.27 Mil) and increased from Dec. 2024 (MXN50,373.27 Mil) to Dec. 2025 (MXN54,642.74 Mil).

Ionis Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Total Liabilities Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37,744.80 38,231.44 44,190.52 50,373.27 54,642.74

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47,815.36 44,312.81 44,303.52 54,642.74 53,350.74
MEX:IONS
65GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ionis Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14072.661+(28986.044+9927.497
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1656.542+0+0)
=54,643

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=63449.134-8806.39
=54,643

Ionis Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12922.071+(29004.768+10058.009
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1365.887+0+0)
=53,351

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=62212.256-8861.521
=53,351

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of MXN53,351 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Total Liabilities of MXN53,351 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Liabilities too high?
Ionis Pharmaceuticals' current Total Liabilities is MXN53,351 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Liabilities compare to EXEL and BBIO?
Ionis Pharmaceuticals' Total Liabilities of MXN53,351 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Liabilities is MXN53,351 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Total Liabilities of MXN53,351 Mil. The stock's GF Value™ is MXN782.91, compared to a current price of MXN1,150.00 — trading 46.9% above its estimated fair value. The current Total Liabilities is MXN53,351 Mil. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Total Liabilities is MXN53,351 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 46.9% above its estimated GF Value™ of MXN782.91.

Key valuation signals for MEX:IONS:

  • Total Liabilities: MXN53,351 Mil
  • GF Value™: MXN782.91 vs. price of MXN1,150.00 (46.9% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for MEX:IONS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN782.91
GF Value